Idarucizumab Antibody is a research-grade biosimilar monoclonal antibody targeting Dabigatran Etexilate Mesylate. Format: Fab-G1-kappa (humanized host). Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis. • Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial., PMID:33290737 • Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism., PMID:35699915 • The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market., PMID:37044200 • Dose tailoring of dabigatran etexilate: obvious or excessive?, PMID:25994994 • A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects., PMID:31652461 • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis., PMID:28693366 • Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation., PMID:28185082 • Direct oral anticoagulants: evidence and unresolved issues., PMID:33248499 • Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta., PMID:24807346 • The discovery of dabigatran etexilate for the treatment of venous thrombosis., PMID:27159158
